Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides

Joost P. Schanstra; Petra Zuerbig; Alaa Alkhalaf; Angel Argiles; Stephan J. L. Bakker; Joachim Beige; Henk J. G. Bilo; Christos Chatzikyrkou; Mohammed Dakna; Jesse Dawson; Christian Delles; Hermann Haller; Marion Haubitz; Holger Husi; Joachim Jankowski; George Jerums; Nanne Kleefstra; Tatiana Kuznetsova; David M. Maahs; Jan Menne; William Mullen; Alberto Ortiz; Frederik Persson; Peter Rossing; Piero Ruggenenti; Ivan Rychlik; Andreas L. Serra; Justyna Siwy; Janet Snell-Bergeon; Goce Spasovski; Jan A. Staessen; Antonia Vlahou; Harald Mischak; Raymond Vanholder

doi:10.1681/ASN.2014050423

Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides

Joost P. Schanstra, Petra Zuerbig^*, Alaa Alkhalaf, Angel Argiles, Stephan J. L. Bakker, Joachim Beige, Henk J. G. Bilo, Christos Chatzikyrkou, Mohammed Dakna, Jesse Dawson, Christian Delles, Hermann Haller, Marion Haubitz, Holger Husi, Joachim Jankowski, George Jerums, Nanne Kleefstra, Tatiana Kuznetsova, David M. Maahs, Jan MenneWilliam Mullen, Alberto Ortiz, Frederik Persson, Peter Rossing, Piero Ruggenenti, Ivan Rychlik, Andreas L. Serra, Justyna Siwy, Janet Snell-Bergeon, Goce Spasovski, Jan A. Staessen, Antonia Vlahou, Harald Mischak, Raymond Vanholder

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

211 Citations (Scopus)

Abstract

Progressive CKD is generally detected at a late stage by a sustained decline in eGFR and/or the presence of significant albuminuria. With the aim of early and improved risk stratification of patients with CKD, we studied urinary peptides in a large cross-sectional multicenter cohort of 1990 individuals, including 522 with follow-up data, using proteome analysis. We validated that a previously established multipeptide urinary biomarker classifier performed significantly better in detecting and predicting progression of CKD than the current clinical standard, urinary albumin. The classifier was also more sensitive for identifying patients with rapidly progressing CKD. Compared with the combination of baseline eGFR and albuminuria (area under the curve [AUC]=0.758), the addition of the multipeptide biomarker classifier significantly improved CKD risk prediction (AUC=0.831) as assessed by the net reclassification index (0.303 +/--0.065; P

Original language	English
Pages (from-to)	1999-2010
Number of pages	12
Journal	Journal of the American Society of Nephrology
Volume	26
Issue number	8
DOIs	https://doi.org/10.1681/ASN.2014050423
Publication status	Published - Aug-2015

Keywords

CHRONIC KIDNEY-DISEASE
IMPROVING GLOBAL OUTCOMES
DIABETIC-NEPHROPATHY
POSITION STATEMENT
PROTEOMIC ANALYSIS
ALBUMIN EXCRETION
RISK
BIOMARKERS
INJURY
NEED

Access to Document

10.1681/ASN.2014050423

Handle.net

Persistent link

Embargoed Document

Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides
Final publisher's version, 680 KB
Request copy

Cite this

Schanstra, J. P., Zuerbig, P., Alkhalaf, A., Argiles, A., Bakker, S. J. L., Beige, J., Bilo, H. J. G., Chatzikyrkou, C., Dakna, M., Dawson, J., Delles, C., Haller, H., Haubitz, M., Husi, H., Jankowski, J., Jerums, G., Kleefstra, N., Kuznetsova, T., Maahs, D. M., ... Vanholder, R. (2015). Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. Journal of the American Society of Nephrology, 26(8), 1999-2010. https://doi.org/10.1681/ASN.2014050423

@article{04be82d8a6d64c1bb7120f3e5dfc696e,

title = "Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides",

abstract = "Progressive CKD is generally detected at a late stage by a sustained decline in eGFR and/or the presence of significant albuminuria. With the aim of early and improved risk stratification of patients with CKD, we studied urinary peptides in a large cross-sectional multicenter cohort of 1990 individuals, including 522 with follow-up data, using proteome analysis. We validated that a previously established multipeptide urinary biomarker classifier performed significantly better in detecting and predicting progression of CKD than the current clinical standard, urinary albumin. The classifier was also more sensitive for identifying patients with rapidly progressing CKD. Compared with the combination of baseline eGFR and albuminuria (area under the curve [AUC]=0.758), the addition of the multipeptide biomarker classifier significantly improved CKD risk prediction (AUC=0.831) as assessed by the net reclassification index (0.303 +/--0.065; P",

keywords = "CHRONIC KIDNEY-DISEASE, IMPROVING GLOBAL OUTCOMES, DIABETIC-NEPHROPATHY, POSITION STATEMENT, PROTEOMIC ANALYSIS, ALBUMIN EXCRETION, RISK, BIOMARKERS, INJURY, NEED",

author = "Schanstra, {Joost P.} and Petra Zuerbig and Alaa Alkhalaf and Angel Argiles and Bakker, {Stephan J. L.} and Joachim Beige and Bilo, {Henk J. G.} and Christos Chatzikyrkou and Mohammed Dakna and Jesse Dawson and Christian Delles and Hermann Haller and Marion Haubitz and Holger Husi and Joachim Jankowski and George Jerums and Nanne Kleefstra and Tatiana Kuznetsova and Maahs, {David M.} and Jan Menne and William Mullen and Alberto Ortiz and Frederik Persson and Peter Rossing and Piero Ruggenenti and Ivan Rychlik and Serra, {Andreas L.} and Justyna Siwy and Janet Snell-Bergeon and Goce Spasovski and Staessen, {Jan A.} and Antonia Vlahou and Harald Mischak and Raymond Vanholder",

note = "Copyright {\textcopyright} 2015 by the American Society of Nephrology.",

year = "2015",

month = aug,

doi = "10.1681/ASN.2014050423",

language = "English",

volume = "26",

pages = "1999--2010",

journal = "Journal of the American Society of Nephrology",

issn = "1046-6673",

publisher = "AMER SOC NEPHROLOGY",

number = "8",

}

Schanstra, JP, Zuerbig, P, Alkhalaf, A, Argiles, A, Bakker, SJL, Beige, J, Bilo, HJG, Chatzikyrkou, C, Dakna, M, Dawson, J, Delles, C, Haller, H, Haubitz, M, Husi, H, Jankowski, J, Jerums, G, Kleefstra, N, Kuznetsova, T, Maahs, DM, Menne, J, Mullen, W, Ortiz, A, Persson, F, Rossing, P, Ruggenenti, P, Rychlik, I, Serra, AL, Siwy, J, Snell-Bergeon, J, Spasovski, G, Staessen, JA, Vlahou, A, Mischak, H & Vanholder, R 2015, 'Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides', Journal of the American Society of Nephrology, vol. 26, no. 8, pp. 1999-2010. https://doi.org/10.1681/ASN.2014050423

TY - JOUR

T1 - Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides

AU - Schanstra, Joost P.

AU - Zuerbig, Petra

AU - Alkhalaf, Alaa

AU - Argiles, Angel

AU - Bakker, Stephan J. L.

AU - Beige, Joachim

AU - Bilo, Henk J. G.

AU - Chatzikyrkou, Christos

AU - Dakna, Mohammed

AU - Dawson, Jesse

AU - Delles, Christian

AU - Haller, Hermann

AU - Haubitz, Marion

AU - Husi, Holger

AU - Jankowski, Joachim

AU - Jerums, George

AU - Kleefstra, Nanne

AU - Kuznetsova, Tatiana

AU - Maahs, David M.

AU - Menne, Jan

AU - Mullen, William

AU - Ortiz, Alberto

AU - Persson, Frederik

AU - Rossing, Peter

AU - Ruggenenti, Piero

AU - Rychlik, Ivan

AU - Serra, Andreas L.

AU - Siwy, Justyna

AU - Snell-Bergeon, Janet

AU - Spasovski, Goce

AU - Staessen, Jan A.

AU - Vlahou, Antonia

AU - Mischak, Harald

AU - Vanholder, Raymond

PY - 2015/8

Y1 - 2015/8

N2 - Progressive CKD is generally detected at a late stage by a sustained decline in eGFR and/or the presence of significant albuminuria. With the aim of early and improved risk stratification of patients with CKD, we studied urinary peptides in a large cross-sectional multicenter cohort of 1990 individuals, including 522 with follow-up data, using proteome analysis. We validated that a previously established multipeptide urinary biomarker classifier performed significantly better in detecting and predicting progression of CKD than the current clinical standard, urinary albumin. The classifier was also more sensitive for identifying patients with rapidly progressing CKD. Compared with the combination of baseline eGFR and albuminuria (area under the curve [AUC]=0.758), the addition of the multipeptide biomarker classifier significantly improved CKD risk prediction (AUC=0.831) as assessed by the net reclassification index (0.303 +/--0.065; P

AB - Progressive CKD is generally detected at a late stage by a sustained decline in eGFR and/or the presence of significant albuminuria. With the aim of early and improved risk stratification of patients with CKD, we studied urinary peptides in a large cross-sectional multicenter cohort of 1990 individuals, including 522 with follow-up data, using proteome analysis. We validated that a previously established multipeptide urinary biomarker classifier performed significantly better in detecting and predicting progression of CKD than the current clinical standard, urinary albumin. The classifier was also more sensitive for identifying patients with rapidly progressing CKD. Compared with the combination of baseline eGFR and albuminuria (area under the curve [AUC]=0.758), the addition of the multipeptide biomarker classifier significantly improved CKD risk prediction (AUC=0.831) as assessed by the net reclassification index (0.303 +/--0.065; P

KW - CHRONIC KIDNEY-DISEASE

KW - IMPROVING GLOBAL OUTCOMES

KW - DIABETIC-NEPHROPATHY

KW - POSITION STATEMENT

KW - PROTEOMIC ANALYSIS

KW - ALBUMIN EXCRETION

KW - RISK

KW - BIOMARKERS

KW - INJURY

KW - NEED

U2 - 10.1681/ASN.2014050423

DO - 10.1681/ASN.2014050423

M3 - Article

C2 - 25589610

SN - 1046-6673

VL - 26

SP - 1999

EP - 2010

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

IS - 8

ER -

Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides

Abstract

Keywords

Access to Document

Handle.net

Embargoed Document

Fingerprint

Cite this